Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (→T) |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
||
| Line 1: | Line 1: | ||
=Guidelines= | =Guidelines= | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
'''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.''' | '''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.''' | ||
==Chemotherapy safety standards== | ==Chemotherapy safety standards== | ||
| Line 29: | Line 26: | ||
''This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound.'' | ''This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound.'' | ||
==A== | ==A== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Abarelix (Plenaxis)]] | *[[Abarelix (Plenaxis)]] | ||
*[[Abemaciclib (Verzenio)]] | *[[Abemaciclib (Verzenio)]] | ||
| Line 70: | Line 64: | ||
==B== | ==B== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Bacillus Calmette-Guérin (BCG)]] | *[[Bacillus Calmette-Guérin (BCG)]] | ||
| Line 104: | Line 95: | ||
==C== | ==C== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Cabazitaxel (Jevtana)]] | *[[Cabazitaxel (Jevtana)]] | ||
| Line 142: | Line 130: | ||
==D== | ==D== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Dabrafenib (Tafinlar)]] | *[[Dabrafenib (Tafinlar)]] | ||
| Line 171: | Line 156: | ||
==E== | ==E== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Elotuzumab (Empliciti)]] | *[[Elotuzumab (Empliciti)]] | ||
| Line 194: | Line 176: | ||
==F== | ==F== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Fam-trastuzumab deruxtecan (Enhertu)]] | *[[Fam-trastuzumab deruxtecan (Enhertu)]] | ||
*[[Fedratinib (Inrebic)]] | *[[Fedratinib (Inrebic)]] | ||
| Line 210: | Line 189: | ||
==G== | ==G== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Gallium Ga 68 gozetotide (Locametz)]] | *[[Gallium Ga 68 gozetotide (Locametz)]] | ||
| Line 224: | Line 200: | ||
==H== | ==H== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Heptaplatin (Sunpla)]] | *[[Heptaplatin (Sunpla)]] | ||
| Line 235: | Line 208: | ||
==I== | ==I== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Ibritumomab tiuxetan (Zevalin)]] | *[[Ibritumomab tiuxetan (Zevalin)]] | ||
| Line 270: | Line 240: | ||
==L== | ==L== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Lanreotide (Somatuline)]] | *[[Lanreotide (Somatuline)]] | ||
*[[Lanreotide LAR (Somatuline Depot)]] | *[[Lanreotide LAR (Somatuline Depot)]] | ||
| Line 295: | Line 262: | ||
==M== | ==M== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Margetuximab (Margenza)]] | *[[Margetuximab (Margenza)]] | ||
*[[Mechlorethamine (Mustargen)]] | *[[Mechlorethamine (Mustargen)]] | ||
| Line 320: | Line 284: | ||
==N== | ==N== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Naxitamab (Danyelza)]] | *[[Naxitamab (Danyelza)]] | ||
| Line 345: | Line 306: | ||
==O== | ==O== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Obinutuzumab (Gazyva)]] | *[[Obinutuzumab (Gazyva)]] | ||
*[[Octreotide (Sandostatin)]] | *[[Octreotide (Sandostatin)]] | ||
| Line 359: | Line 317: | ||
==P== | ==P== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Paclitaxel (Taxol)]] | *[[Paclitaxel (Taxol)]] | ||
| Line 395: | Line 350: | ||
==R== | ==R== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Radium Ra 223 (Xofigo)]] | *[[Radium Ra 223 (Xofigo)]] | ||
| Line 425: | Line 377: | ||
==S== | ==S== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Sacituzumab govitecan (Trodelvy)]] | *[[Sacituzumab govitecan (Trodelvy)]] | ||
| Line 448: | Line 397: | ||
==T== | ==T== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Tafasitamab (Monjuvi)]] | *[[Tafasitamab (Monjuvi)]] | ||
*[[Tagraxofusp (Elzonris)]] | *[[Tagraxofusp (Elzonris)]] | ||
| Line 494: | Line 440: | ||
==U== | ==U== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Umbralisib (Ukoniq)]] '''FDA approved 2/5/2021''' | *[[Umbralisib (Ukoniq)]] '''FDA approved 2/5/2021''' | ||
==V== | ==V== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Valrubicin (Valstar)]] | *[[Valrubicin (Valstar)]] | ||
*[[Vandetanib (Caprelsa)]] | *[[Vandetanib (Caprelsa)]] | ||
| Line 520: | Line 460: | ||
==Z== | ==Z== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Zanubrutinib (Brukinsa)]] | *[[Zanubrutinib (Brukinsa)]] | ||
*[[Ziv-aflibercept (Zaltrap)]] | *[[Ziv-aflibercept (Zaltrap)]] | ||
| Line 531: | Line 468: | ||
==A== | ==A== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Aminopterin]] | *[[Aminopterin]] | ||
*[[Asparaginase (Elspar)]] | *[[Asparaginase (Elspar)]] | ||
==D== | ==D== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Daunorubicin liposomal (DaunoXome)]] | *[[Daunorubicin liposomal (DaunoXome)]] | ||
*[[Denileukin diftitox (Ontak)]] | *[[Denileukin diftitox (Ontak)]] | ||
| Line 548: | Line 479: | ||
==E== | ==E== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Edrecolomab (Panorex)]] | *[[Edrecolomab (Panorex)]] | ||
==F== | ==F== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Floxuridine (FUDR)]] | *[[Floxuridine (FUDR)]] | ||
*[[Fluoxymesterone (Halotestin)]] | *[[Fluoxymesterone (Halotestin)]] | ||
| Line 564: | Line 489: | ||
==L== | ==L== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Levamisole (Ergamisol)]] | *[[Levamisole (Ergamisol)]] | ||
==M== | ==M== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Melphalan flufenamide (Pepaxto)]] | *[[Melphalan flufenamide (Pepaxto)]] | ||
==O== | ==O== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Olaratumab (Lartruvo)]] | *[[Olaratumab (Lartruvo)]] | ||
==P== | ==P== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Plicamycin (Mithracin)]] | *[[Plicamycin (Mithracin)]] | ||
==S== | ==S== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Semustine (MeCCNU)]] | *[[Semustine (MeCCNU)]] | ||
==T== | ==T== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Testolactone (Teslac)]] | *[[Testolactone (Teslac)]] | ||
==U== | ==U== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Uracil mustard]] | *[[Uracil mustard]] | ||
*[[Urethane]] | *[[Urethane]] | ||
| Line 616: | Line 520: | ||
''This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.'' | ''This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.'' | ||
==A== | ==A== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Abexinostat (PCI-24781)]] | *[[Abexinostat (PCI-24781)]] | ||
*[[Actinium Ac 225 lintuzumab (Actimab-A)]] | *[[Actinium Ac 225 lintuzumab (Actimab-A)]] | ||
| Line 635: | Line 536: | ||
==B== | ==B== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Barasertib (AZD1152)]] | *[[Barasertib (AZD1152)]] | ||
*[[Bavituximab (PGN401)]] | *[[Bavituximab (PGN401)]] | ||
| Line 647: | Line 545: | ||
==C== | ==C== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Capivasertib (AZD5363)]] | *[[Capivasertib (AZD5363)]] | ||
*[[Catumaxomab (Removab)]] '''in US clinical trials''' | *[[Catumaxomab (Removab)]] '''in US clinical trials''' | ||
| Line 660: | Line 555: | ||
==D== | ==D== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Dalpiciclib (SHR6390)]] | *[[Dalpiciclib (SHR6390)]] | ||
*[[Denintuzumab mafodotin (SGN-CD19A)]] | *[[Denintuzumab mafodotin (SGN-CD19A)]] | ||
| Line 672: | Line 564: | ||
==E== | ==E== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Emepepimut-S (Stimuvax)]] | *[[Emepepimut-S (Stimuvax)]] | ||
*[[Ensartinib (X-396)]] | *[[Ensartinib (X-396)]] | ||
| Line 685: | Line 574: | ||
==F== | ==F== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Filanesib (ARRY-520)]] | *[[Filanesib (ARRY-520)]] | ||
*[[Flumatinib (HH-GV-678)]] | *[[Flumatinib (HH-GV-678)]] | ||
| Line 695: | Line 581: | ||
==G== | ==G== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[G207]] | *[[G207]] | ||
*[[Galeterone (TOK-001)]] | *[[Galeterone (TOK-001)]] | ||
| Line 709: | Line 592: | ||
==H== | ==H== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[HER2 peptide vaccine (AE37)]] | *[[HER2 peptide vaccine (AE37)]] | ||
*[[Hu5F9-G4]] | *[[Hu5F9-G4]] | ||
==I== | ==I== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Idasanutlin (RG7388)]] | *[[Idasanutlin (RG7388)]] | ||
*[[IMA901]] | *[[IMA901]] | ||
| Line 733: | Line 610: | ||
==L== | ==L== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Lapuleucel-T (DN24-02)]] | *[[Lapuleucel-T (DN24-02)]] | ||
*[[Lestaurtinib (CEP-701)]] | *[[Lestaurtinib (CEP-701)]] | ||
| Line 746: | Line 620: | ||
==M== | ==M== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Mapatumumab (HGS-ETR1)]] | *[[Mapatumumab (HGS-ETR1)]] | ||
*[[Masitinib (AB1010)]] | *[[Masitinib (AB1010)]] | ||
| Line 761: | Line 632: | ||
==O== | ==O== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Olaptesed pegol (NOX-A12)]] | *[[Olaptesed pegol (NOX-A12)]] | ||
*[[Onartuzumab (MetMAb)]] | *[[Onartuzumab (MetMAb)]] | ||
| Line 773: | Line 641: | ||
==P== | ==P== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Pentraxin 2 (PRM-151)]] | *[[Pentraxin 2 (PRM-151)]] | ||
*[[Perifosine (KRX-0401)]] | *[[Perifosine (KRX-0401)]] | ||
| Line 792: | Line 657: | ||
==R== | ==R== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Refametinib (BAY 869766)]] | *[[Refametinib (BAY 869766)]] | ||
*[[Reovirus (Reolysin)]] | *[[Reovirus (Reolysin)]] | ||
| Line 806: | Line 668: | ||
==S== | ==S== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Sapacitabine (CS-682)]] | *[[Sapacitabine (CS-682)]] | ||
*[[Sapanisertib (MLN0128)]] | *[[Sapanisertib (MLN0128)]] | ||
| Line 819: | Line 678: | ||
==T== | ==T== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Tabalumab (LY2127399)]] | *[[Tabalumab (LY2127399)]] | ||
*[[Tamibarotene (Amnoid)]] | *[[Tamibarotene (Amnoid)]] | ||
| Line 841: | Line 697: | ||
==U== | ==U== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Ublituximab (TG-1101)]] | *[[Ublituximab (TG-1101)]] | ||
*[[UCART19]] | *[[UCART19]] | ||
==V== | ==V== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Vadastuximab talirine (SGN-CD33A)]] | *[[Vadastuximab talirine (SGN-CD33A)]] | ||
*[[Varlilumab (CDX-1127)]] | *[[Varlilumab (CDX-1127)]] | ||
| Line 862: | Line 712: | ||
==Z== | ==Z== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Zandelisib (ME-401)]] | *[[Zandelisib (ME-401)]] | ||
| Line 871: | Line 718: | ||
==A== | ==A== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Abciximab (ReoPro)]] | *[[Abciximab (ReoPro)]] | ||
*[[Acetaminophen (Tylenol)]] | *[[Acetaminophen (Tylenol)]] | ||
| Line 904: | Line 748: | ||
==B== | ==B== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Betrixaban (Bevyxxa)]] | *[[Betrixaban (Bevyxxa)]] | ||
*[[Bismuth subsalicylate (Pepto-Bismol)]] | *[[Bismuth subsalicylate (Pepto-Bismol)]] | ||
| Line 913: | Line 754: | ||
==C== | ==C== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Cangrelor (Kengreal)]] | *[[Cangrelor (Kengreal)]] | ||
*[[Calcium phosphate rinse (Caphosol)]] | *[[Calcium phosphate rinse (Caphosol)]] | ||
| Line 934: | Line 772: | ||
==D== | ==D== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Dabigatran (Pradaxa)]] | *[[Dabigatran (Pradaxa)]] | ||
*[[Dalteparin (Fragmin)]] | *[[Dalteparin (Fragmin)]] | ||
| Line 961: | Line 796: | ||
==E== | ==E== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Eculizumab (Soliris)]] | *[[Eculizumab (Soliris)]] | ||
*[[Edoxaban (Savaysa)]] | *[[Edoxaban (Savaysa)]] | ||
| Line 981: | Line 813: | ||
==F== | ==F== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Factor VIIa, recombinant (NovoSeven RT)]] | *[[Factor VIIa, recombinant (NovoSeven RT)]] | ||
*[[Factor VIII, human]] | *[[Factor VIII, human]] | ||
| Line 1,017: | Line 846: | ||
==G== | ==G== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Glucarpidase (Voraxaze)]] | *[[Glucarpidase (Voraxaze)]] | ||
*[[Granisetron (Kytril)]] | *[[Granisetron (Kytril)]] | ||
| Line 1,027: | Line 853: | ||
==H== | ==H== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Haloperidol (Haldol)]] | *[[Haloperidol (Haldol)]] | ||
*[[Hematopoetic progenitor cells, cord blood (Hemacord)]] | *[[Hematopoetic progenitor cells, cord blood (Hemacord)]] | ||
==I== | ==I== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Ibandronate (Boniva)]] | *[[Ibandronate (Boniva)]] | ||
*[[Idarucizumab (Praxbind)]] | *[[Idarucizumab (Praxbind)]] | ||
| Line 1,047: | Line 867: | ||
==L== | ==L== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Lactulose]] | *[[Lactulose]] | ||
*[[Lamivudine (Epivir)]] | *[[Lamivudine (Epivir)]] | ||
| Line 1,065: | Line 882: | ||
==M== | ==M== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Mannitol]] | *[[Mannitol]] | ||
| Line 1,079: | Line 893: | ||
==N== | ==N== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Nabilone (Cesamet)]] | *[[Nabilone (Cesamet)]] | ||
| Line 1,088: | Line 899: | ||
==O== | ==O== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Olanzapine (Zyprexa)]] | *[[Olanzapine (Zyprexa)]] | ||
*[[Omeprazole (Prilosec)]] | *[[Omeprazole (Prilosec)]] | ||
| Line 1,098: | Line 906: | ||
==P== | ==P== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Palifermin (Kepivance)]] | *[[Palifermin (Kepivance)]] | ||
| Line 1,133: | Line 938: | ||
==R== | ==R== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Rabeprazole (Aciphex)]] | *[[Rabeprazole (Aciphex)]] | ||
| Line 1,151: | Line 953: | ||
==S== | ==S== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Sargramostim (Leukine)]] | *[[Sargramostim (Leukine)]] | ||
*[[Scopolamine (Scopoderm)]] | *[[Scopolamine (Scopoderm)]] | ||
| Line 1,162: | Line 961: | ||
==T== | ==T== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Tacrolimus (Prograf)]] | *[[Tacrolimus (Prograf)]] | ||
*[[Tbo-filgrastim (Granix)]] | *[[Tbo-filgrastim (Granix)]] | ||
| Line 1,184: | Line 980: | ||
==V== | ==V== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Valacyclovir (Valtrex)]] | *[[Valacyclovir (Valtrex)]] | ||
*[[Valganciclovir (Valcyte)]] | *[[Valganciclovir (Valcyte)]] | ||
| Line 1,198: | Line 991: | ||
==W== | ==W== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Warfarin (Coumadin)]] | *[[Warfarin (Coumadin)]] | ||
| Line 1,214: | Line 1,004: | ||
==Cytotoxic Chemotherapy== | ==Cytotoxic Chemotherapy== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:Alkylating agents|Alkylating agents]] | *[[:Category:Alkylating agents|Alkylating agents]] | ||
| Line 1,233: | Line 1,020: | ||
==[[:Category:Kinase inhibitors|Kinase inhibitors]]== | ==[[:Category:Kinase inhibitors|Kinase inhibitors]]== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2"> | <div style="column-count:2;-moz-column-count:2;-webkit-column-count:2"> | ||
*[[:Category:AKT1 inhibitors|AKT1 inhibitors]] | *[[:Category:AKT1 inhibitors|AKT1 inhibitors]] | ||
| Line 1,270: | Line 1,054: | ||
==[[:Category:Endocrine therapeutic|Endocrine therapy]]== | ==[[:Category:Endocrine therapeutic|Endocrine therapy]]== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:Antiandrogens|Antiandrogens]] | *[[:Category:Antiandrogens|Antiandrogens]] | ||
| Line 1,292: | Line 1,073: | ||
==Biologics== | ==Biologics== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:Antibody medications|Antibody medications]] | *[[:Category:Antibody medications|Antibody medications]] | ||
| Line 1,306: | Line 1,084: | ||
==Supportive Medications== | ==Supportive Medications== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:Antibacterials|Antibacterials]] | *[[:Category:Antibacterials|Antibacterials]] | ||
| Line 1,329: | Line 1,104: | ||
==[[:Category:Hematology medications|Benign Hematology Medications]]== | ==[[:Category:Hematology medications|Benign Hematology Medications]]== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:Anticoagulants|Anticoagulants]] | *[[:Category:Anticoagulants|Anticoagulants]] | ||
| Line 1,351: | Line 1,123: | ||
==[[:Category:Hematopoietic growth factors|Hematopoietic Growth Factors]]== | ==[[:Category:Hematopoietic growth factors|Hematopoietic Growth Factors]]== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:Erythrocyte growth factors|Erythrocyte growth factors]] | *[[:Category:Erythrocyte growth factors|Erythrocyte growth factors]] | ||
| Line 1,361: | Line 1,130: | ||
==Miscellaneous== | ==Miscellaneous== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:REMS_program|Drugs in a REMS program]] | *[[:Category:REMS_program|Drugs in a REMS program]] | ||
| Line 1,373: | Line 1,139: | ||
==Medications by Condition== | ==Medications by Condition== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
*[[:Category:B-cell acute lymphoblastic leukemia medications|Acute lymphocytic leukemia medications]] | *[[:Category:B-cell acute lymphoblastic leukemia medications|Acute lymphocytic leukemia medications]] | ||
| Line 1,448: | Line 1,211: | ||
==[[:Category:Routed medications|Medications by Route of Administration]]== | ==[[:Category:Routed medications|Medications by Route of Administration]]== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[:Category:Intra-arterial medications|Intraarterial (IA) medications]] | *[[:Category:Intra-arterial medications|Intraarterial (IA) medications]] | ||
| Line 1,463: | Line 1,223: | ||
==Medications by Year of Approval== | ==Medications by Year of Approval== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
*[[:Category:FDA approved in 1939|FDA approved in 1939]] | *[[:Category:FDA approved in 1939|FDA approved in 1939]] | ||
| Line 1,541: | Line 1,298: | ||
=Interesting and Helpful Links= | =Interesting and Helpful Links= | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
*[[Antidepressants and other psychiatric medications in cancer care]] | *[[Antidepressants and other psychiatric medications in cancer care]] | ||
Revision as of 11:18, 26 July 2022
Guidelines
Other interesting and helpful links can be found by clicking the link.
Chemotherapy safety standards
- 2020: Dillmon et al. Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards PubMed
- 2019: Celano et al. Safe handling of hazardous drugs: ASCO standards PubMed
- 2016: Neuss et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology
- 2010: Carrington et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy PubMed
Dose adjustments
- 2021: Griggs et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update
Older
- 2012: Griggs et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline[1]
Antimicrobials
Growth factors
- 2015: Update of ASCO Clinical Practice Guideline recommendations for the use of WBC growth factors[2]
Approved antineoplastics
This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound.
A
- Abarelix (Plenaxis)
- Abemaciclib (Verzenio)
- Abiraterone (Zytiga)
- Acalabrutinib (Calquence)
- Aclarubicin (Aclacinomycin)
- Ado-trastuzumab emtansine (Kadcyla)
- Afatinib (Gilotrif)
- Aldesleukin (Proleukin)
- Alectinib (Alecensa)
- Alemtuzumab (Campath)
- Alitretinoin (Panretin)
- All-trans retinoic acid (ATRA)
- Alpelisib (Piqray)
- Altretamine (Hexalen)
- Alvocidib (Flavopiridol)
- Amifostine (Ethyol)
- Aminoglutethimide (Cytadren)
- Amivantamab (Rybrevant) FDA approved 5/21/2021
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anastrozole (Arimidex)
- Ancestim (Stemgen)
- Apalutamide (Erleada)
- Apatinib (Aitan)
- Arsenic trioxide (Trisenox)
- Asciminib (Scemblix) FDA approved 10/29/2021
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Asparaginase erwinia chrysanthemi-rywn (Rylaze) FDA approved 6/30/2021
- Atezolizumab (Tecentriq)
- Avapritinib (Ayvakit)
- Avelumab (Bavencio)
- Axicabtagene ciloleucel (Yescarta)
- Axitinib (Inlyta)
- Azacitidine (Onureg)
- Azacitidine (Vidaza)
B
- Bacillus Calmette-Guérin (BCG)
- Belantamab mafodotin (Blenrep)
- Belinostat (Beleodaq)
- Belotecan (Camptobell)
- Belumosudil (Rezurock) FDA approved 7/16/2021
- Belzutifan (Welireg) FDA approved 8/13/2021
- Bendamustine
- Benralizumab (Fasenra)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Binimetinib (Mektovi)
- Bleomycin (Blenoxane)
- Blinatumomab (Blincyto)
- Bortezomib (Velcade)
- Bosutinib (Bosulif)
- Brentuximab vedotin (Adcetris)
- Brexucabtagene autoleucel (Tecartus)
- Brigatinib (Alunbrig)
- Buserelin (Suprefact)
- Busulfan (Myleran)
C
- Cabazitaxel (Jevtana)
- Cabozantinib (Cabometyx)
- Cabozantinib (Cometriq)
- Calaspargase (Asparlas)
- Capecitabine (Xeloda)
- Caplacizumab (Cablivi)
- Capmatinib (Tabrecta)
- Carboplatin (Paraplatin)
- Carfilzomib (Kyprolis)
- Carmustine (BCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- Caspofungin (Cancidas)
- Cemiplimab (Libtayo)
- Ceritinib (Zykadia)
- Cetuximab (Erbitux)
- Chidamide (Epidaza)
- Chlorambucil (Leukeran)
- Chlorozotocin (DCNU)
- Ciltacabtagene autoleucel (Carvykti) FDA approved 3/1/2022
- Cisplatin (Platinol)
- Cladribine (Leustatin)
- Clofarabine (Clolar)
- Cobimetinib (Cotellic)
- Copanlisib (Aliqopa)
- Cortisone
- Crizotinib (Xalkori)
- Cyclophosphamide (Cytoxan)
- Cyproterone acetate (Androcur)
- Cytarabine (Ara-C)
- Cytarabine and daunorubicin liposomal (Vyxeos)
- Cytarabine liposomal (DepoCyt)
D
- Dabrafenib (Tafinlar)
- Dacarbazine (DTIC)
- Dacomitinib (Vizimpro)
- Dactinomycin (Cosmegen)
- Daratumumab (Darzalex)
- Daratumumab and hyaluronidase (Darzalex Faspro)
- Darolutamide (Nubeqa)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Decitabine (Dacogen)
- Decitabine and cedazuridine (Inqovi)
- Degarelix (Firmagon)
- Dexamethasone (Decadron)
- Dinutuximab (Unituxin)
- Docetaxel (Taxotere)
- Dostarlimab (Jemperli) FDA approved 4/22/2021
- Doxifluridine (Didox)
- Doxorubicin (Adriamycin)
- Pegylated liposomal doxorubicin (Doxil)
- Durvalumab (Imfinzi)
- Dutasteride (Avodart)
- Duvelisib (Copiktra)
E
- Elotuzumab (Empliciti)
- Emapalumab (Gamifant)
- Enasidenib (Idhifa)
- Encorafenib (Braftovi)
- Enfortumab vedotin (Padcev)
- Entrectinib (Rozlytrek)
- Enzalutamide (Xtandi)
- Epirubicin (Ellence)
- Erdafitinib (Balversa)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estradiol
- Estramustine (Emcyt)
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Fam-trastuzumab deruxtecan (Enhertu)
- Fedratinib (Inrebic)
- Fluorouracil (5-FU)
- Fludarabine (Fludara)
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Forodesine (Fodosine)
- Fostamatinib (Tavalisse)
- Fotemustine (Muphoran)
- Fulvestrant (Faslodex)
G
- Gallium Ga 68 gozetotide (Locametz)
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemtuzumab ozogamicin (Mylotarg)
- Gilteritinib (Xospata)
- Glasdegib (Daurismo)
- Goserelin (Zoladex)
H
I
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (Imbruvica)
- Icotinib (Conmana)
- Idarubicin (Idamycin)
- Idecabtagene vicleucel (Abecma) FDA approved 3/26/2021
- Idelalisib (Zydelig)
- Ifosfamide (Ifex)
- Imatinib (Gleevec)
- Infigratinib (Truseltiq) FDA approved 5/28/2021
- Inotuzumab ozogamicin (Besponsa)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- Interferon gamma-1b (Actimmune)
- Iobenguane I 131 (Azedra)
- Iodine-131
- Ipilimumab (Yervoy)
- Iptacopan (LNP023)
- Irinotecan (Camptosar)
- Irinotecan liposome (Onivyde)
- Isatuximab (Sarclisa)
- Isotretinoin (Accutane)
- Ivosidenib (Tibsovo)
- Ixabepilone (Ixempra)
- Ixazomib (Ninlaro)
K
L
- Lanreotide (Somatuline)
- Lanreotide LAR (Somatuline Depot)
- Lapatinib (Tykerb)
- Larotrectinib (Vitrakvi)
- Lasofoxifene (Fablyn) not FDA approved
- Lenalidomide (Revlimid)
- Lenvatinib (Lenvima)
- Letermovir (Prevymis)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Lisocabtagene maraleucel (Breyanzi) FDA approved 2/5/2021
- Lobaplatin (D-19466)
- Lomustine (CCNU)
- Loncastuximab tesirine (Zynlonta) FDA approved 4/23/2021
- Lorlatinib (Lorbrena)
- Lurbinectedin (Zepzelca)
- Lutetium Lu 177 dotatate (Lutathera)
- Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) FDA approved 3/23/2022
M
- Margetuximab (Margenza)
- Mechlorethamine (Mustargen)
- Medroxyprogesterone (MPA)
- Megestrol (Megace)
- Melphalan (Alkeran)
- Mepolizumab (Nucala)
- Mercaptopurine (6-MP)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Methylprednisolone (Solumedrol)
- Midostaurin (Rydapt)
- Mifamurtide (Mepact)
- Mitomycin (Jelmyto)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- Mobocertinib (Exkivity) FDA approved on 9/15/2021
- Mogamulizumab (Poteligeo)
- Moxetumomab pasudotox (Lumoxiti)
N
- Naxitamab (Danyelza)
- Necitumumab (Portrazza)
- Nedaplatin (Aqupla)
- Nelarabine (Arranon)
- NEOD001
- Neratinib (Nerlynx)
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- Nimotuzumab (Theraloc)
- Nimustine (ACNU)
- Nintedanib (Vargatef)
- Niraparib (Zejula)
- Nivolumab (Opdivo)
- Nivolumab and relatlimab (Opdualag) FDA approved 3/18/2022
- Nolatrexed (Thymitaq)
- Non-pegylated liposomal doxorubicin (Myocet)
- Norethandrolone (Nilevar)
- NovoTTF-100A system (Optune)
O
- Obinutuzumab (Gazyva)
- Octreotide (Sandostatin)
- Octreotide LAR (Sandostatin LAR)
- Ofatumumab (Arzerra)
- Olaparib (Lynparza)
- Omacetaxine (Synribo)
- Osimertinib (Tagrisso)
- Oxaliplatin (Eloxatin)
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Paclitaxel, polymeric micelle-bound (Genexol-PM)
- Pacritinib (Vonjo) FDA approved 3/1/2022
- Palbociclib (Ibrance)
- Panitumumab (Vectibix)
- Panobinostat (Farydak)
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (Sylatron)
- Pembrolizumab (Keytruda)
- Pemetrexed (Alimta)
- Pemigatinib (Pemazyre)
- Pentostatin (Nipent)
- Pertuzumab (Perjeta)
- Pertuzumab & Trastuzumab hyaluronidase (Phesgo)
- Pexidartinib (Turalio)
- Pirarubicin (THP)
- Pixantrone (Pixuvri)
- Polatuzumab vedotin (Polivy)
- Pomalidomide (Pomalyst)
- Ponatinib (Iclusig)
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Pralsetinib (Gavreto)
- Prednisone (Sterapred)
- Prednisolone (Millipred)
- Procarbazine (Matulane)
R
- Radium Ra 223 (Xofigo)
- Radotinib (Supect)
- Raltitrexed (Tomudex)
- Ramucirumab (Cyramza)
- Ranimustine (Cymerin)
- Ravulizumab (Ultomiris)
- Realgar-Indigo naturalis formulation
- Regorafenib (Stivarga)
- Relugolix (Orgovyx)
- Ribociclib (Kisqali)
- Ripretinib (Qinlock)
- Rituximab (Rituxan)
- Rituximab and hyaluronidase human (Rituximab Hycela)
- Romidepsin (Istodax)
- Rucaparib (Rubraca)
- Ruxolitinib (Jakafi)
S
- Sacituzumab govitecan (Trodelvy)
- Samarium-153 (Quadramet)
- Selinexor (Xpovio)
- Selpercatinib (Retevmo)
- Selumetinib (Koselugo)
- Sintilimab (Tyvyt)
- Sipuleucel-T (Provenge)
- Sirolimus protein-bound particles (Fyarro) FDA approved 11/22/2021
- Sonidegib (Odomzo)
- Sorafenib (Nexavar)
- Sotorasib (Lumakras) FDA approved 5/28/2021
- Stilbamidine
- Streptozocin (Zanosar)
- Strontium-89 (Metastron)
- Sunitinib (Sutent)
- Suramin (Antrypol)
T
- Tafasitamab (Monjuvi)
- Tagraxofusp (Elzonris)
- Talazoparib (Talzenna)
- Talimogene laherparepvec (Imlygic)
- Tamoxifen (Nolvadex)
- Tasonermin (Beromun)
- Tazemetostat (Tazverik)
- Tegafur and uracil (UFT)
- Tegafur, gimeracil, oteracil (Teysuno, S-1)
- Telotristat (Xermelo)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Tepotinib (Tepmetko) FDA approved 2/3/2021
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Tepadina)
- Thiotepa (Thioplex)
- Tisagenlecleucel (Kymriah)
- Tisotumab vedotin (Tivdak) FDA approved 9/20/2021
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Toripalimab (Tuoyi)
- Tositumomab and I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trametinib (Mekinist)
- Trastuzumab (Herceptin)
- Trastuzumab and hyaluronidase (Herceptin Hylecta)
- Treosulfan (Ovastat)
- Trifluridine and tipiracil (Lonsurf)
- Trilostane (Vetoryl)
- Trimetrexate (Neutrexin)
- Triptorelin (Trelstar LA)
- Tucatinib (Tukysa)
U
- Umbralisib (Ukoniq) FDA approved 2/5/2021
V
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Vemurafenib (Zelboraf)
- Venetoclax (Venclexta)
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo)
- Vindesine (Eldisine)
- Vinflunine (Javlor)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge)
- Vorinostat (Zolinza)
- Voxelotor (Oxbryta)
Z
Discontinued antineoplastics
This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc), but are no longer on the market. Note that it is possible that these drugs continue to be available in some limited way, such as through compassionate use programs.
A
D
E
F
L
M
O
P
S
T
U
Investigational antineoplastics
This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.
A
- Abexinostat (PCI-24781)
- Actinium Ac 225 lintuzumab (Actimab-A)
- Adagrasib (MRTX849)
- Adavosertib (MK-1775)
- Adebrelimab (SHR-1316)
- Adenovirus-interferon-γ (TG1042)
- Afuresertib (GSK2110183)
- Alisertib (MLN8237)
- Amatuximab (MORAb-009)
- AMG 330
- Amonafide (Quinamed)
- Apocept (APG101)
- Astuprotimut-R (GSK1572932A)
B
- Barasertib (AZD1152)
- Bavituximab (PGN401)
- Belagenpumatucel-L (Lucanix)
- BHQ880
- BL22 immunotoxin (CAT-3888)
- Buparlisib (BKM120)
C
- Capivasertib (AZD5363)
- Catumaxomab (Removab) in US clinical trials
- Cediranib (Recentin)
- Cixutumumab (IMC-A12)
- Coltuximab ravtansine (CoR, SAR3419)
- Crenolanib (CP-868,596)
- Custirsen (OGX-011)
D
- Dalpiciclib (SHR6390)
- Denintuzumab mafodotin (SGN-CD19A)
- Dinaciclib (SCH 727965)
- Discodermolide (XAA296)
- DMUC5754A
- Dovitinib (TKI-258)
E
- Emepepimut-S (Stimuvax)
- Ensartinib (X-396)
- Entinostat (SNDX-275)
- Entospletinib (GS-9973)
- Epcoritamab (GEN-3013)
- Epratuzumab (LymphoCide)
- Etirinotecan pegol (NKTR-102)
F
G
- G207
- Galeterone (TOK-001)
- Galunisertib (LY2157299)
- Ganetespib (STA-9090)
- Ganitumab (AMG 479)
- Gemcitabine elaidate (CP-4126, CO-101)
- Glembatumumab vedotin (CDX-011)]
- Guadecitabine (SGI-110)
H
I
- Idasanutlin (RG7388)
- IMA901
- Imetelstat (GRN163L)
- Indatuximab ravtansine (BT062)
- Ipatasertib (GDC-0068)
- IPH 2101
J
L
- Lapuleucel-T (DN24-02)
- Lestaurtinib (CEP-701)
- Linifanib (ABT-869)
- Linsitinib (OSI-906)
- Lorvotuzumab mertansine (BB-10901)
- Lutetium-177-PSMA-617
- LY3023414
M
- Mapatumumab (HGS-ETR1)
- Masitinib (AB1010)
- Milataxel (TL139)
- Mirvetuximab soravtansine (IMGN853)
- MK2206
- Mocetinostat (MGCD0103)
- Momelotinib (CYT387)
- MOR208
- Motesanib (AMG 706)
O
- Olaptesed pegol (NOX-A12)
- Onartuzumab (MetMAb)
- Oprozomib (ONX 0912)
- Orteronel (TAK-700)
- Osocimab (BAY 1213790)
- Otlertuzumab (TRU-016)
P
- Pentraxin 2 (PRM-151)
- Perifosine (KRX-0401)
- Phosphomannopentaose sulfate (PI-88)
- Pictilisib (GDC-0941)
- Pidilizumab (CT-011)
- Pinatuzumab vedotin (DCDT2980S)
- Pirtobrutinib (LOXO-305)
- Plinabulin (NPI-2358)
- Pracinostat (SB939)
Q
R
- Refametinib (BAY 869766)
- Reovirus (Reolysin)
- Retaspimycin (IPI-504)
- Ricolinostat (ACY-1215, Rocilinostat)
- Ridaforolimus (AP23573)
- Rilotumumab (AMG 102)
- Rociletinib (CO-1686)
- Ropeginterferon alfa-2b (AOP2014)
S
- Sapacitabine (CS-682)
- Sapanisertib (MLN0128)
- Seliciclib (CYC202)
- Semuloparin (AVE5026)
- Spebrutinib (CC-292)
- Surufatinib (HMPL-012)
- Sutimlimab (BIVV009)
T
- Tabalumab (LY2127399)
- Tamibarotene (Amnoid)
- Tasadenoturev (DNX-2401)
- Tebentafusp (IMCgp100)
- Teclistamab (JNJ 64007957)
- Tesetaxel (DJ-927)
- Tesevatinib (XL647)
- Tigatuzumab (CS-1008)
- Tipifarnib (Zarnestra)
- Tirabrutinib (GS-4059)
- Tislelizumab (BGB-A317)
- Tivantinib (ARQ 197)
- Tivozanib (AV-951)
- Tosedostat (CHR-2797)
- Trebananib (AMG 386)
- Tremelimumab (ticilimumab)
U
V
- Vadastuximab talirine (SGN-CD33A)
- Varlilumab (CDX-1127)
- Veliparib (ABT-888)
- Veltuzumab (hA20)
- Volasertib (BI 6727)
- Vosaroxin (SNS 595)
- Voxtalisib (XL765)
Z
Supportive and other medications
A
- Abciximab (ReoPro)
- Acetaminophen (Tylenol)
- Acetazolamide (Diamox)
- Acyclovir (Zovirax)
- Alendronate (Fosamax)
- Alizapride (Litican)
- Allopurinol (Zyloprim)
- Alprazolam (Xanax)
- Aminocaproic acid (Amicar)
- Amoxicillin
- Anagrelide (Agrylin)
- Anti-inhibitor coagulant complex (FEIBA NF)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin, horse ATG (Atgam)
- Antithymocyte globulin, rabbit ATG (Grafalon)
- Antithymocyte globulin, rabbit ATG (Thymoglobulin)
- Apixaban (Eliquis)
- Aprepitant (Emend)
- Argatroban (Acova)
- Aripiprazole (Abilify)
- Ascorbic acid (Vitamin C)
- Aspirin
- Aspirin and dipyridamole (Aggrenox)
- Atropine (Atropen)
- Atovaquone (Mepron)
- Avatrombopag (Doptelet)
- Azathioprine (Imuran)
B
C
- Cangrelor (Kengreal)
- Calcium phosphate rinse (Caphosol)
- Cetirizine (Zyrtec)
- Chlorpheniramine (Chlor-Trimeton)
- Cilostazol (Pletal)
- Cimetidine (Tagamet)
- Ciprofloxacin (Cipro)
- Clarithromycin (Biaxin)
- Clemastine (Tavist)
- Clodronate (Bonefos)
- Clopidogrel (Plavix)
- Crizanlizumab (Adakveo)
- Cyanocobalamin (Vitamin B12)
- Cyclosporine
- Cytomegalovirus Immune Globulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dalteparin (Fragmin)
- Danazol (Danocrine)
- Dapsone (Aczone)
- Darbepoetin alfa (Aranesp)
- Deferasirox (Exjade)
- Deferasirox (Jadenu)
- Deferiprone (Ferriprox)
- Deferoxamine (Desferal)
- Defibrotide (Defitelio)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexchlorpheniramine (Polaramine)
- Dexrazoxane (Zinecard)
- Diphenhydramine (Benadryl)
- Dipyridamole (Persantine)
- Docusate (Colace)
- Dolasetron (Anzemet)
- Domperidone (Motilium)
- Doxycycline
- Dronabinol (Marinol)
E
- Eculizumab (Soliris)
- Edoxaban (Savaysa)
- Eltrombopag (Promacta)
- Emicizumab-kxwh (Hemlibra)
- Enoxaparin (Lovenox)
- Epoetin alfa (Procrit)
- Epoetin zeta (Eprex)
- Eptifibatide (Integrilin)
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human
- Factor VIII, recombinant
- Factor IX, human
- Factor IX, recombinant
- Factor IX, recombinant, Fc fusion protein (Alprolix)
- Factor X, human (Coagadex)
- Factor Xa, recombinant, inactivated-zhzo (Andexxa)
- Factor XIII concentrate, human (Corifact)
- Famciclovir (Famvir)
- Famotidine (Pepcid)
- Ferric carboxymaltose (Injectafer)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Fibrinogen concentrate, human (RiaSTAP)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fluconazole (Diflucan)
- Folic acid (Folate)
- Fondaparinux (Arixtra)
- Fosaprepitant (Emend for Injection)
- Furosemide (Lasix)
G
H
I
- Ibandronate (Boniva)
- Idarucizumab (Praxbind)
- Indomethacin (Indocin)
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Itraconazole (Sporanox)
L
- Lactulose
- Lamivudine (Epivir)
- Lansoprazole (Prevacid)
- Lenograstim (Granocyte)
- Lepirudin (Refludan) discontinued
- Levofloxacin (Levaquin)
- L-glutamine (Endari)
- Lipefilgrastim (XM22) in clinical trials
- Loperamide (Imodium)
- Lorazepam (Ativan)
- Luspatercept (Reblozyl)
- Lusutrombopag (Mulpleta)
M
- Mannitol
- Meperidine (Demerol)
- Mesna (Mesnex)
- Methyltesterone (Android)
- Metoclopramide (Reglan)
- Mitapivat (AG-348) in clinical trials
- Mycophenolate mofetil (CellCept)
N
O
P
- Palifermin (Kepivance)
- Palonosetron (Aloxi)
- Pamidronate (Aredia)
- Pantoprazole (Protonix)
- Pegfilgrastim (Neulasta)
- Penicillin V
- Pentamidine (Nebupent)
- Phenytoin (Dilantin)
- Phytonadione (Vitamin K)
- Plerixafor (Mozobil)
- Prasugrel (Effient)
- Pravastatin (Pravachol)
- Prochlorperazine (Compazine)
- Promethazine (Phenergan)
- Protamine sulfate
- Prothrombin Complex Concentrate, human
Q
R
- Rabeprazole (Aciphex)
- Raloxifene (Evista)
- Ramosetron (Iribo)
- Ranitidine (Zantac)
- Rasburicase (Elitek)
- Rho(D) immune globulin (RhoGAM)
- Rilzabrutinib (PRN-1008)
- Risedronate (Actonel)
- Rivaroxaban (Xarelto)
- Rolapitant (Varubi)
- Romiplostim (Nplate)
S
- Sargramostim (Leukine)
- Scopolamine (Scopoderm)
- Sennosides (Senna)
- Siltuximab (Sylvant)
- Sirolimus (Rapamune)
T
- Tacrolimus (Prograf)
- Tbo-filgrastim (Granix)
- Ticagrelor (Brilinta)
- Ticlodipine (Ticlid)
- Tinzaparin (Innohep)
- Tirofiban (Aggrastat)
- Tocilizumab (Actemra)
- Tofacitinib (Xeljanz)
- Tranexamic acid (Cyklokapron)
- Trilaciclib (Cosela)
- Trimethoprim-Sulfamethoxazole (Bactrim DS)
- Tropisetron (Navoban)
U
V
- Valacyclovir (Valtrex)
- Valganciclovir (Valcyte)
- Valoctocogene roxaparvovec (AAV5-hFVIII-SQ)
- Valproate (Depakote)
- von Willebrand factor and factor VIII complex, human
- von Willebrand factor, recombinant
- Vorapaxar (Zontivity)
- Voriconazole (Vfend)
W
Z
By Category
Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).
Drugs in a REMS program
Cytotoxic Chemotherapy
- Alkylating agents
- Anthracyclines
- Antimetabolites
- DNA synthesis inhibitors
- Microtubule inhibitors
- Nitrogen mustards
- Nitrosureas
- Platinum agents
- Proteasome inhibitors
- Taxanes
- Topoisomerase inhibitors
- Vinca alkaloids
Kinase inhibitors
- AKT1 inhibitors
- ALK inhibitors
- Aurora kinase inhibitors
- AXL inhibitors
- Bcr-Abl inhibitors
- BRAF inhibitors
- BTK inhibitors
- CDK inhibitors
- EGFR inhibitors
- ERBB2 inhibitors
- ERBB4 inhibitors
- FGFR inhibitors
- FLT3 inhibitors
- IGFR inhibitors
- JAK inhibitors
- KIT inhibitors
- MEK inhibitors
- MET inhibitors
- mTOR inhibitors
- PDGFR inhibitors
- PI3K inhibitors
- PLK1 inhibitors
- RET inhibitors
- ROS1 inhibitors
- SRC inhibitors
- SYK inhibitors
- TEK inhibitors
- TRK inhibitors
- VEGF inhibitors
Endocrine therapy
- Antiandrogens
- Steroid synthesis inhibitors
- Androgen receptor inhibitors
- 5 alpha-reductase inhibitors
- GnRH agonists
- GnRH antagonists
- Aromatase inhibitors
- Selective estrogen receptor modulators
- Steroids
- Somatostatin analogs
Investigational and Discontinued
Biologics
- Antibody medications
- Antibody-drug conjugates
- Anti-HER2 medications
- IL-6 inhibitors
- Enzymes
- Immunotherapy
- Immunomodulatory drugs (IMiDs)
Supportive Medications
- Antibacterials
- Antidiarrheals
- Antifungals
- Antihistamines
- Antivirals
- Bisphosphonates
- Chemotherapy protective agents
- Emesis prevention
- PCP prophylaxis
- RANK ligand inhibitors
- Steroids
Radioactive agents
Benign Hematology Medications
Hematopoietic Growth Factors
Miscellaneous
- Drugs in a REMS program
- HDAC inhibitors
- Hypomethylating agents
- Retinoids
- WHO Essential Cancer Medicines
Medications by Condition
- Acute lymphocytic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Cancer of unknown primary medications
- Castleman’s disease medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Cervical cancer medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Chronic myelogenous leukemia medications
- Chronic myelomonocytic leukemia medications
- Colon cancer medications
- Cutaneous T-cell lymphoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal cancer medications
- Essential thrombocythemia medications
- Extranodal NK/T-cell lymphoma, nasal type lymphoma medications
- Follicular lymphoma medications
- Gastric cancer medications
- Hairy cell leukemia medications
- Head and neck cancer medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Immune thrombocytopenic purpura (ITP) medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Multiple myeloma medications
- Myelodysplastic syndrome medications
- Myelofibrosis medications
- NK/T-cell lymphoma medications
- Non-small cell lung cancer medications
- Neuroendocrine tumor medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Paroxysmal nocturnal hemoglobinuria (PNH) medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Polycythemia vera medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Rectal cancer medications
- Renal cell carcinoma medications
- Sarcoma medications
- Sickle cell anemia medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Testicular cancer medications
- Thymoma medications
- Thyroid cancer medications
- Transformed lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
Medications by Route of Administration
- Intraarterial (IA) medications
- Intracavitary medications
- Intramuscular (IM) medications
- Intrathecal (IT) medications
- Intravenous (IV) medications
- Intravesicular medications
- Oral (PO) medications
- Subcutaneous (SC) medications
Medications by Year of Approval
- FDA approved in 1939
- FDA approved in 1941
- FDA approved in 1946
- FDA approved in 1949
- FDA approved in 1951
- FDA approved in 1952
- FDA approved in 1953
- FDA approved in 1954
- FDA approved in 1955
- FDA approved in 1956
- FDA approved in 1957
- FDA approved in 1958
- FDA approved in 1959
- FDA approved in 1962
- FDA approved in 1963
- FDA approved in 1964
- FDA approved in 1965
- FDA approved in 1966
- FDA approved in 1967
- FDA approved in 1968
- FDA approved in 1969
- FDA approved in 1970
- FDA approved in 1971
- FDA approved in 1973
- FDA approved in 1974
- FDA approved in 1975
- FDA approved in 1976
- FDA approved in 1977
- FDA approved in 1978
- FDA approved in 1979
- FDA approved in 1980
- FDA approved in 1981
- FDA approved in 1982
- FDA approved in 1983
- FDA approved in 1984
- FDA approved in 1985
- FDA approved in 1986
- FDA approved in 1987
- FDA approved in 1988
- FDA approved in 1989
- FDA approved in 1990
- FDA approved in 1991
- FDA approved in 1992
- FDA approved in 1993
- FDA approved in 1994
- FDA approved in 1995
- FDA approved in 1996
- FDA approved in 1997
- FDA approved in 1998
- FDA approved in 1999
- FDA approved in 2000
- FDA approved in 2001
- FDA approved in 2002
- FDA approved in 2003
- FDA approved in 2004
- FDA approved in 2005
- FDA approved in 2006
- FDA approved in 2007
- FDA approved in 2008
- FDA approved in 2009
- FDA approved in 2010
- FDA approved in 2011
- FDA approved in 2012
- FDA approved in 2013
- FDA approved in 2014
- FDA approved in 2015
- FDA approved in 2016
- FDA approved in 2017
- FDA approved in 2018
- FDA approved in 2019
Interesting and Helpful Links
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline (2013)
- 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society (ASCO/ONS) Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology
- Chemotherapy Administration Sequence[3] - with chemotherapy sequencing chart
- The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. PubMed
- CredibleMeds.org - lists of QT-prolonging drugs; requires free registration to see full list
- FDA drug shortages list
- ASHP drug shortages list - also includes information about discontinued drugs
- DailyMed - a comprehensive NLM portal to all FDA-approved drugs
- Drugs@FDA - the main portal into the FDA drug database
- The NCI Drug Dictionary - an extensive resource with most antineoplastics (approved and in clinical trials) listed
- In the Pipeline - a blog from a veteran of the pharmaceutical industry, Derek Lowe. General but much is cancer-relevant. The old home of this blog is no longer active.
- Steroid conversions
- Vesicant & irritant chemotherapy
- Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers
- CPIC Guidelines The Clinical Pharmacogenetics Implementation Consortium provides guidelines for a small set of drugs with pharmacogenetically-guided dosing implications, some of which are oncologics
References
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article